Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias
- 1 September 2005
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 130 (5) , 716-725
- https://doi.org/10.1111/j.1365-2141.2005.05679.x
Abstract
Recent studies suggest that the prosurvival signal transduction pathway involving phosphoinositide 3-kinase (PI3K)/Akt can confer an aggressive, apoptosis-resistant phenotype to acute leukaemia cells. We have investigated the effect of modulating this signalling pathway on the sensitivity of leukaemic cell lines (NB-4, CEM, Jurkat, MOLT-4) and acute promyelocytic primary blasts to apoptosis induced by 1 micromol/l As2O3. Whereas parental NB-4 cells did not display any phosphorylated (active) Akt, CEM, Jurkat and MOLT-4 cells exhibited high levels of Akt activation. Consistently, treatment of NB-4 cells with pharmacological inhibitors of the PI3K/Akt pathway (LY294002, wortmannin) did not increase sensitivity of these cells to arsenic trioxide (As2O3), whereas siRNA knock-down of Akt enhanced As2O3-induced apoptosis of CEM, Jurkat and MOLT-4 cells. Overexpression of a constitutively active Akt cDNA rendered NB-4 cells less susceptible to As2O3. Upon prolonged exposure to As2O3, we isolated a NB-4 cell clone that was resistant to As2O3 and displayed high levels of active Akt. LY294002 treatment of acute promyelocytic primary blasts with elevated Akt phosphorylation levels resulted in an increased sensitivity to As2O3. These results may provide a rationale for the development of combined or sequential treatment with PI3K/Akt inhibitors to improve the efficacy of As2O3 on acute leukaemias and also to overcome As2O3 resistance.Keywords
This publication has 37 references indexed in Scilit:
- Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathwayBritish Journal of Haematology, 2005
- Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic MalignanciesJournal of Clinical Oncology, 2005
- New therapeutic approaches for adult T-cell leukaemiaThe Lancet Oncology, 2004
- Advances in protein kinase B signalling: AKTion on multiple frontsTrends in Biochemical Sciences, 2004
- The potential of arsenic trioxide in the treatment of malignant disease: past, present, and futureLeukemia Research, 2004
- Structure, regulation and function of PKB/AKT—a major therapeutic targetBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2004
- The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27Kip1 and control of cyclin D1 expressionLeukemia, 2003
- Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systemsProceedings of the National Academy of Sciences, 2001
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 2001
- Serine/Threonine Protein Kinases and ApoptosisExperimental Cell Research, 2000